Asia-Pacific’s pharmaceutical sector is expected to record 4.2% growth from 2022 to 2027, with China and Japan dominating the sector in terms of value. Generics dominate the regions based on volume, directly impacting innovator molecule uptake. Nevertheless, Asia-Pacific is establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region.
• What does the competitive landscape look like?
• Which factor drives higher pharmaceutical product prices in the Philippines compared to other ASEAN countries?
• How did China emerge as a biopharma innovation hub?
Sign up for a complimentary Growth Pipeline Dialog™
A Growth Pipeline Dialog is a structured open discussion with our growth experts providing unparalleled industry intelligence, technology advancements, and proven implementation best practices. This discussion will spark innovative thinking and help generate a pipeline of growth opportunities you can leverage to maximize your company’s future growth potential.
